Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Caribou Biosciences ( (CRBU) ) just unveiled an update.
On June 18, 2025, Caribou Biosciences announced that it had regained compliance with Nasdaq’s listing requirements, specifically maintaining a minimum closing bid price of $1.00 per share. This compliance, achieved between June 3 and June 17, 2025, ensures the company’s continued listing on the Nasdaq Global Select Market, which is crucial for its market presence and investor confidence.
The most recent analyst rating on (CRBU) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Caribou Biosciences stock, see the CRBU Stock Forecast page.
Spark’s Take on CRBU Stock
According to Spark, TipRanks’ AI Analyst, CRBU is a Neutral.
The overall score is driven primarily by the company’s weak financial performance, marked by declining revenues and significant losses, which pose a risk to financial stability. The technical analysis provides some optimism with positive momentum, although the valuation remains unattractive due to negative earnings. Without additional positive corporate developments or earnings insights, the stock remains a high-risk investment primarily for speculative or growth-focused investors.
To see Spark’s full report on CRBU stock, click here.
More about Caribou Biosciences
Caribou Biosciences, Inc. operates in the biotechnology industry, focusing on developing transformative therapies through CRISPR genome editing technology.
Average Trading Volume: 1,131,051
Technical Sentiment Signal: Hold
Current Market Cap: $124.6M
See more insights into CRBU stock on TipRanks’ Stock Analysis page.